ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Acquired by Millennium Management LLC

Millennium Management LLC boosted its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 1,005.8% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 230,079 shares of the specialty pharmaceutical company's stock after purchasing an additional 209,272 shares during the quarter. Millennium Management LLC owned about 1.10% of ANI Pharmaceuticals worth $14,651,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Innealta Capital LLC bought a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $65,000. Ridgewood Investments LLC purchased a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth approximately $85,000. SG Americas Securities LLC purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $106,000. ADAR1 Capital Management LLC bought a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at approximately $132,000. Finally, Clear Street Markets LLC purchased a new stake in ANI Pharmaceuticals during the 4th quarter valued at $140,000. 76.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

ANIP has been the subject of a number of recent analyst reports. StockNews.com cut shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, September 7th. Raymond James boosted their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research report on Wednesday, September 18th. Truist Financial reiterated a "hold" rating and issued a $60.00 price target (down from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday, September 11th. Finally, HC Wainwright reissued a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $78.80.

ANI Pharmaceuticals Stock Down 3.4 %

Shares of ANIP stock traded down $1.99 during mid-day trading on Monday, hitting $55.84. The stock had a trading volume of 220,783 shares, compared to its average volume of 213,464. The firm has a market capitalization of $1.17 billion, a P/E ratio of 35.15 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. ANI Pharmaceuticals, Inc. has a 12-month low of $48.20 and a 12-month high of $70.81. The firm's 50-day moving average is $60.16 and its two-hundred day moving average is $63.09.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, beating analysts' consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The business had revenue of $138.00 million for the quarter, compared to the consensus estimate of $129.09 million. During the same quarter last year, the firm posted $1.06 EPS. The company's revenue for the quarter was up 18.5% on a year-over-year basis. On average, analysts predict that ANI Pharmaceuticals, Inc. will post 3.58 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Muthusamy Shanmugam sold 11,000 shares of the firm's stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $63.38, for a total transaction of $697,180.00. Following the sale, the chief operating officer now owns 671,620 shares of the company's stock, valued at $42,567,275.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders have sold 26,007 shares of company stock worth $1,642,990. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.